Revolution Medicines

Director, Clinical Data Management

Redwood City, California, United States · Director · Full-time

Sponsorship not specified$211k-$264kDetected 23 hours ago

GCPComplianceProject ManagementAuditingICD-10Clinical TrialsFDA RegulatoryLeadershipCommunicationMentoring

About the role

Acts as primary liaison with CROs, third party data vendors, EDC vendors.
Reviews clinical protocols and cross functional plans.
Serves as primary reviewer or author of case report forms (CRFs) and CRF completion guidelines.

Demonstrated ability to multi-task, prioritize options, anticipate challenges, and execute on goals as a member of an interdisciplinary team is extremely important.
The Director, Clinical Data Management, will be required to collaborate closely with other functional leaders to ensure clinical trial success.

MS, BS/BA degree, or other suitable qualification with relevance to the field.
15 or more years' direct experience of designing and running early-stage or late-stage clinical trials.
Good working knowledge of ICH, FDA, and GCP regulations and guidelines.
A demonstrable record of strong leadership and teamwork.
Excellent written and verbal communication skills.
Experience from industry is essential.
Oncology experience, especially in solid tumors.
5 or more years' direct line management experience.
#LI-Hybrid #LI-DN1
The base pay salary range for this full-time position for candidates working onsite at our headquarters in Redwood City, CA is listed below.

$211,000 - $264,000 USD
Please note that Revolution Medicines does not extend unsolicited employment offers and will never ask candidates to provide financial information, purchase equipment, or pay fees as part of the hiring process.

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers.
The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins.
The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

This listing is sourced directly from Revolution Medicines's careers page and normalized into a canonical job model.